Background and Aims. Fast-acting insulin aspart (FIASP®) administered by continuous subcutaneous insulin infusion (CSII) shows, in comparison to conventional insulin aspart (IAsp), a faster on and faster off action, and more than double insulin action during the first 30’ of infusion. However, there are no studies aimed to compare the effectiveness of FIASP® and IAsp in subjects treated with CSII in a real life-setting.Materials and Methods. We studied 17 adult subjects (13 males; age = 43.1 years ± 10.4 DS; HbA1c at baseline = 6.98% ± 1.13 DS) with type 1 diabetes, treated with CSII by Medtronic Minimed ® 640G system. Main outcomes were: difference of mean and coefficient of variation (CV) of glucose measurements (GM) obtained during 2 weeks of continuous glucose monitoring (CGM), respectively 2 weeks before and after switch from IAsp to FIASP®; the number of drop-outs.Results. After switch the mean of GM was not different (153,4 mg% ± 20.7 DS vs 154,3 ± 17,8 DS; n.s.; Figure 1), but CV of GM decreased significantly (32.7% ± 4.9% DS vs 28,6% ± 3.8% DS; P < 0.05; Figure 2). We recorded one drop-out for problems in the infusion site and 3 drop-outs in subjects who needed to increase basal insulin infusion rate more than 2 times with FIASP®.Discussion and Conclusions. The pharmacokinetic properties of FIASP® may be advantageous for subjects using CSII because it decreases glycemic variability without increasing mean GM, but we need to better understand how to optimize the insulin infusion rates.
No datasets are available for this submission.
No license information is available for this submission.